The five-year trial will test the antibody crenezumab in Colombian carriers of the Paisa mutation in presenilin-1, and in some U.S. carriers of other presenilin and APP mutations. At the Alzheimer's Disease Research Summit 2012 in Washington, D.C., NIH Director Francis Collins announced that the trial, as well as a second trial of intranasal insulin in MCI, were part of the National Plan to Address Alzheimer’s Disease, which HHS Secretary Kathleen Sebelius released on 15 May 2012.
NIH Director Announces $100M Prevention Trial of Genentech Antibody
Q&A With Genentech Lead Scientist on API Trial Ryan Watts

Click image to view video

“I think about moving my hand and wrist…it feels natural.” The woman in this video is paralyzed. She talks about her experience controlling the robotic arm via a sensor in her brain. Using this brain-computer interface, she is serving herself a sip of coffee for the first time since her stroke 15 years ago.

The research is part of the BrainGate pilot trial to restore motor ability to people who have lost a limb or are paralyzed from injury or disease. The coffee exercise and another target-grabbing activity represent the first time people using a computer interface have completed complex, three-dimensional motions. Read the full story. Video courtesy of Nature